Immunotherapy: Constructive Approach for Breast Cancer Treatment

References

• García-Aranda M, Redondo M. Immunotherapy: a challenge of breast cancer treatment. Cancers. 2019;11(12):1822. doi:10.3390/cancers11121822
   PubMed Web of Science ®Google Scholar
• Liu JP, Chen W, Schwarer AP, Li H. Telomerase in cancer immunotherapy. Biochim Biophys Acta. 2010;1805(1):35–42.
   PubMed Web of Science ®Google Scholar
• Adams S, Gatti-Mays ME, Kalinsky K, et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 2019;5(8):1205–1214. doi:10.1001/jamaoncol.2018.7147
   PubMed Web of Science ®Google Scholar
• Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354–1360. doi:10.1001/jamaoncol.2016.1061
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor microenvironment. Medicina. 2019;56(1):15. doi:10.3390/medicina56010015
   PubMed Web of Science ®Google Scholar
• Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. doi:10.1016/j.breast.2022.08.010
   PubMed Web of Science ®Google Scholar
• Fatima N, Liu L, Hong S, et al. Prediction of breast cancer, comparative review of machine learning techniques, and their analysis. IEEE Access. 2020;8:150360–150376. doi:10.1109/ACCESS.2020.3016715
   Google Scholar
• Mohammed SI, Torres-Luquis O, Zhou W, et al. Tumor-draining lymph secretome en route to the regional lymph node in breast cancer metastasis. Breast Cancer. 2020;57–67.
   PubMed Web of Science ®Google Scholar
• Finn OJ. The Dawn of vaccines for cancer prevention. Nature Rev Immunol. 2018;18(3):183–194. doi:10.1038/nri.2017.140
   PubMed Web of Science ®Google Scholar
• Silverstein AM. Paul Ehrlich’s Receptor Immunology: The Magnificent Obsession. Elsevier; 2001.
   Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 2002;3(11):991–998. doi:10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45):5932–5943. doi:10.1038/onc.2008.267
   PubMed Web of Science ®Google Scholar
• Beaven MA. Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol. 2009;39(1):11–25. doi:10.1002/eji.200838899
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–360. doi:10.1146/annurev.immunol.22.012703.104803
   PubMed Web of Science ®Google Scholar
• Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Exp Rev Clin Immunol. 2014;10(1):41–62. doi:10.1586/1744666X.2014.865519
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AK. A review of cancer immunotherapy toxicity. Ca A Cancer J Clin. 2020;70(2):86–104. doi:10.3322/caac.21596
   PubMed Web of Science ®Google Scholar
• Yang Z, Ma Y, Zhao H, et al. Nanotechnology platforms for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12(2):e1590. doi:10.1002/wnan.1590
   PubMed Web of Science ®Google Scholar
• Klein G. Tumor antigens. Ann Rev Microbiol. 1966;20(1):223–252. doi:10.1146/annurev.mi.20.100166.001255
   PubMedGoogle Scholar
• Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science. 1991;254(5035):1153–1160. doi:10.1126/science.1957167
   PubMed Web of Science ®Google Scholar
• Chaudhuri S, Cariappa A, Tang M, et al. Genetic susceptibility to breast cancer: HLA DQB* 03032 and HLA DRB1* 11 may represent protective alleles. Proc Natl Acad Sci. 2000;97(21):11451–11454. doi:10.1073/pnas.97.21.11451
   PubMed Web of Science ®Google Scholar
• Wang Z, Cao YJ. Adoptive cell therapy targeting neoantigens: a frontier for cancer research. Front Immunol. 2020;11:176. doi:10.3389/fimmu.2020.00176
   PubMed Web of Science ®Google Scholar
• Teixeira MR, Pandis N, Heim S. Cytogenetic clues to breast carcinogenesis. Genes Chromosomes Cancer. 2002;33(1):1–16. doi:10.1002/gcc.1206
   PubMed Web of Science ®Google Scholar
• Gil Del Alcazar CR, Huh SJ, Ekram MB, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discovery. 2017;7(10):1098–1115. doi:10.1158/2159-8290.CD-17-0222
   PubMed Web of Science ®Google Scholar
• Criscitiello C. Tumor-associated antigens in breast cancer. Breast Care. 2012;7(4):262–266. doi:10.1159/000342164
   PubMed Web of Science ®Google Scholar
• Nicolini A, Carpi A. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev. 2009;29(3):436–471. doi:10.1002/med.20143
   PubMed Web of Science ®Google Scholar
• VanKlompenberg MK, Bedalov CO, Soto KF, et al. APC selectively mediates response to chemotherapeutic agents in breast cancer. BMC Cancer. 2015;15(1):1–14. doi:10.1186/s12885-015-1456-x
   PubMedGoogle Scholar
• Guđmundsdóttir I, Gunnlaugur Jónasson J, Sigurđsson H, et al. Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int j Cancer. 2000;89(6):500–505.
   PubMed Web of Science ®Google Scholar
• Li B, Geng R, Wu Q, et al. Alterations in immune-related genes as potential marker of prognosis in breast cancer. Front Oncol. 2020;10:333. doi:10.3389/fonc.2020.00333
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nature Rev Drug Discov. 2020;19(3):200–218. doi:10.1038/s41573-019-0052-1
   PubMed Web of Science ®Google Scholar
• van der Burg SH. Correlates of Immune and Clinical Activity of Novel Cancer Vaccines. in Seminars in Immunology. Elsevier; 2018.
   Google Scholar
• Rong L, Li R, Li S, et al. Immunosuppression of breast cancer cells mediated by transforming growth factor-β in exosomes from cancer cells. Oncol Lett. 2016;11(1):500–504. doi:10.3892/ol.2015.3841
   PubMed Web of Science ®Google Scholar
• Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112(9):1421–1427. doi:10.1038/bjc.2015.124
   PubMed Web of Science ®Google Scholar
• Mao H, Zhang L, Yang Y, et al. New insights of CTLA-4 into its biological function in breast cancer. Current Cancer Drug Targets. 2010;10(7):728–736. doi:10.2174/156800910793605811
   PubMed Web of Science ®Google Scholar
• Behranvand N, Nasri F, Zolfaghari Emameh R, et al. Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunother. 2022;71(3):507–526.
   PubMed Web of Science ®Google Scholar
• Sanz-Garcia E, Zhao E, Bratman SV, et al. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges. Sci Adv. 2022;8(4):eabi8618. doi:10.1126/sciadv.abi8618
   PubMed Web of Science ®Google Scholar
• Elez E, Chianese C, Sanz‐García E, et al. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS -mutant metastatic colorectal cancer. Mol Oncol. 2019;13(9):1827–1835. doi:10.1002/1878-0261.12547
   PubMed Web of Science ®Google Scholar
• Gao Q, Feng J, Liu W, et al. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. Adv Drug Delivery Rev. 2022;188:114445. doi:10.1016/j.addr.2022.114445
   PubMed Web of Science ®Google Scholar
• Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biotechnol J. 2006;1(2):138–147. doi:10.1002/biot.200500044
   PubMedGoogle Scholar
• Park W, Heo Y-J, Han DK. New opportunities for nanoparticles in cancer immunotherapy. Biomater Res. 2018;22(1):1–10. doi:10.1186/s40824-018-0133-y
   PubMedGoogle Scholar
• Gross S, Erdmann M, Haendle I, et al. Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients. JCI Insight. 2017;2(8). doi:10.1172/jci.insight.91438
   Web of Science ®Google Scholar
• Till SJ, Francis JN, Nouri-Aria K, et al. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113(6):1025–1034. doi:10.1016/j.jaci.2004.03.024
   PubMed Web of Science ®Google Scholar
• Gp D, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–998.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Soyano AE, Dholaria B, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):1–25. doi:10.1186/s13045-017-0552-6
   PubMedGoogle Scholar
• Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52(1):55–81. doi:10.1016/j.immuni.2019.12.018
   PubMed Web of Science ®Google Scholar
• Kim H, Choi J-M, Lee K-M. Immune checkpoint blockades in triple-negative breast cancer: current state and molecular mechanisms of resistance. Biomedicines. 2022;10(5):1130. doi:10.3390/biomedicines10051130
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74–82. doi:10.1001/jamaoncol.2018.4224
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59. doi:10.1016/S1470-2045(19)30689-8
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Med. 2019;25(6):920–928. doi:10.1038/s41591-019-0432-4
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167(3):671–686. doi:10.1007/s10549-017-4537-5
   PubMed Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–1288. doi:10.1093/annonc/mdz158
   PubMed Web of Science ®Google Scholar
• McArthur HL, Diab A, Page DB, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res. 2016;22(23):5729–5737. doi:10.1158/1078-0432.CCR-16-0190
   PubMed Web of Science ®Google Scholar
• Sabel MS, Nehs MA, Su G, et al. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. 2005;90(1):97–104. doi:10.1007/s10549-004-3289-1
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2010;16(13):3485–3494. doi:10.1158/1078-0432.CCR-10-0505
   PubMed Web of Science ®Google Scholar
• Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med. 2013;34(6):1217–1256. doi:10.1016/j.mam.2013.01.006
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–3720. doi:10.1158/1078-0432.CCR-16-3215
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443–455. doi:10.1016/j.ccell.2020.03.017
   PubMed Web of Science ®Google Scholar
• Sceneay J, Goreczny GJ, Wilson K, et al. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer. Cancer Discov. 2019;9(9):1208–1227. doi:10.1158/2159-8290.CD-18-1454
   PubMed Web of Science ®Google Scholar
• Siddiqui I, Schaeuble K, Chennupati V, et al. Intratumoral Tcf1+ PD-1+ CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50(1):195–211. e10. doi:10.1016/j.immuni.2018.12.021
   PubMed Web of Science ®Google Scholar
• Jansen CS, Prokhnevska N, Master VA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576(7787):465–470. doi:10.1038/s41586-019-1836-5
   PubMed Web of Science ®Google Scholar
• Falvo P, Orecchioni S, Hillje R, et al. Cyclophosphamide and vinorelbine activate stem-like CD8+ T cells and improve anti-PD-1 efficacy in triple-negative breast cancer. Cancer Res. 2021;81(3):685–697. doi:10.1158/0008-5472.CAN-20-1818
   PubMed Web of Science ®Google Scholar
• Xiao Y, Ma D, Zhao S, et al. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25(16):5002–5014. doi:10.1158/1078-0432.CCR-18-3524
   PubMed Web of Science ®Google Scholar
• Wu S-Y, Xiao Y, Wei J-L, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9(7):e002528. doi:10.1136/jitc-2021-002528
   PubMed Web of Science ®Google Scholar
• Loi S, Dushyanthen S, Beavis PA, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res. 2016;22(6):1499–1509. doi:10.1158/1078-0432.CCR-15-1125
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang H-L, Li Z-L, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021;12(1):2672. doi:10.1038/s41467-021-22618-x
   PubMed Web of Science ®Google Scholar
• Hu Q, Ye Y, Chan L-C, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunol. 2019;20(7):835–851. doi:10.1038/s41590-019-0400-7
   PubMed Web of Science ®Google Scholar
• Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33. doi:10.1016/j.molmed.2014.10.009
   PubMed Web of Science ®Google Scholar
• Bin Umair M, Akusa FN, Kashif H, et al. Viruses as tools in gene therapy, vaccine development, and cancer treatment. Arch Virol. 2022;167(6):1387–1404. doi:10.1007/s00705-022-05432-8
   PubMed Web of Science ®Google Scholar
• Gardella B, Gritti A, Soleymaninejadian E, et al. New Perspectives in Therapeutic Vaccines for HPV: a Critical Review. Medicina. 2022;58(7):860. doi:10.3390/medicina58070860
   PubMedGoogle Scholar
• Corti C, Giachetti PPMB, Eggermont AMM, et al. Therapeutic vaccines for breast cancer: has the time finally come? Eur. J. Cancer. 2022;160:150–174. doi:10.1016/j.ejca.2021.10.027
   PubMed Web of Science ®Google Scholar
• Banday AH, Jeelani S, Hruby VJ. Cancer vaccine adjuvants–recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol. 2015;37(1):1–11. doi:10.3109/08923973.2014.971963
   PubMed Web of Science ®Google Scholar
• Luo W, Yang G, Luo W, et al. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Cancer Cell Int. 2020;20(1):1–10. doi:10.1186/s12935-020-1147-9
   PubMed Web of Science ®Google Scholar
• Melief CJ, van Hall T, Arens R, et al. Therapeutic cancer vaccines. J Clin Investig. 2015;125(9):3401–3412. doi:10.1172/JCI80009
   PubMed Web of Science ®Google Scholar
• Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–475. doi:10.1016/B978-0-12-407190-2.00007-1
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu L, Wang Y, et al. A novel therapeutic vaccine based on graphene oxide nanocomposite for tumor immunotherapy. Chin Chem Lett. 2022;33(8):4089–4095. doi:10.1016/j.cclet.2022.01.071
   Web of Science ®Google Scholar
• Shah S, Famta P, Tiwari V, et al. Instigation of the epoch of nanovaccines in cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022;15:e1870.
   PubMed Web of Science ®Google Scholar
• Debien V, De Caluwé A, Wang X, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7. doi:10.1038/s41523-023-00508-3
   PubMed Web of Science ®Google Scholar
• Zhu S-Y, Yu K-D. Breast cancer vaccines: disappointing or promising? Front Immunol. 2022;13:190.
   Web of Science ®Google Scholar
• Huang L, Rong Y, Tang X, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Molecular Cancer. 2022;21(1):1–19. doi:10.1186/s12943-022-01515-x
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. doi:10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Srivastava PK. Therapeutic cancer vaccines. Curr Opinion Immunol. 2006;18(2):201–205. doi:10.1016/j.coi.2006.01.009
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer. 2007;110(8):1677–1686. doi:10.1002/cncr.22978
   PubMed Web of Science ®Google Scholar
• Parkin DM. The global health burden of infection‐associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030–3044. doi:10.1002/ijc.21731
   PubMed Web of Science ®Google Scholar
• Chung MA, Luo Y, O’Donnell M, et al. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine. Cancer Res. 2003;63(6):1280–1287.
   PubMed Web of Science ®Google Scholar
• Islam MR, Islam F, Nafady MH, et al. Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint. Molecules. 2022;27(7):2165. doi:10.3390/molecules27072165
   PubMed Web of Science ®Google Scholar
• Bednarek AK, Sahin A, Brenner AJ, et al. Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. Clin Cancer Res. 1997;3(1):11–16.
   PubMed Web of Science ®Google Scholar
• Disis ML, Cecil DL. Breast cancer vaccines for treatment and prevention. Breast Cancer Res Treat. 2022;191(3):481–489. doi:10.1007/s10549-021-06459-2
   PubMed Web of Science ®Google Scholar
• Hodge JW. Carcinoembryonic antigen as a target for cancer vaccines. CII. 1996;43(3):127–134. doi:10.1007/s002620050313
   Google Scholar
• Beckwith DM, Cudic M. Tumor-Associated O-Glycans of MUC1: Carriers of the Glyco-Code and Targets for Cancer Vaccine Design. in Seminars in Immunology. Elsevier; 2020.
   Google Scholar
• Runnebaum IB, Nagarajan M, Bowman M, et al. Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci. 1991;88(23):10657–10661. doi:10.1073/pnas.88.23.10657
   PubMed Web of Science ®Google Scholar
• Watson MA, Dintzis S, Darrow CM, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res. 1999;59(13):3028–3031.
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci Ö, Chen Y-T, et al. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer. 1998;78(3):387–389. doi:10.1002/(SICI)1097-0215(19981029)78:3<387::AID-IJC22>3.0.CO;2-2
   PubMed Web of Science ®Google Scholar
• Xia J, Tanaka Y, Koido S, et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol. 2003;170(4):1980–1986. doi:10.4049/jimmunol.170.4.1980
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004;10(14):4699–4708. doi:10.1158/1078-0432.CCR-04-0347
   PubMed Web of Science ®Google Scholar
• Tang D-C, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356(6365):152–154. doi:10.1038/356152a0
   PubMed Web of Science ®Google Scholar
• Clifton GT, Hale D, Vreeland TJ, et al. Results of a randomized phase IIb trial of nelipepimut-S+ trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer. Clin Cancer Res. 2020;26(11):2515–2523. doi:10.1158/1078-0432.CCR-19-2741
   PubMed Web of Science ®Google Scholar
• Chick RC, Clifton GT, Hale DF, et al. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol. 2021;225:108679. doi:10.1016/j.clim.2021.108679
   PubMed Web of Science ®Google Scholar
• Ayoub NM, Al-Shami KM, Yaghan RJ. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer. 2019;11:53–69. doi:10.2147/BCTT.S175360
   PubMed Web of Science ®Google Scholar
• Patel S, McWilliams D, Fischette CT, et al. Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, Phase IIb study evaluating the use of HER2/Neu peptide GP2+ GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2-positive. J Clin Oncol. 2021;39:542. doi:10.1200/JCO.2021.39.15_suppl.542
   Web of Science ®Google Scholar
• McCarthy PM, Clifton GT, Vreeland TJ, et al. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence. Exp Opinion Investig Drugs. 2021;30(1):5–11. doi:10.1080/13543784.2021.1849140
   PubMed Web of Science ®Google Scholar
• Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein—based vaccine. J Clin Oncol. 2004;22(10):1916–1925. doi:10.1200/JCO.2004.09.005
   PubMed Web of Science ®Google Scholar
• Arab A, Yazdian-Robati R, Behravan J. HER2-positive breast cancer immunotherapy: a focus on vaccine development. Arch Immunol Therapiae Exp. 2020;68(1):1–18. doi:10.1007/s00005-019-00566-1
   PubMed Web of Science ®Google Scholar
• Park JW, Melisko ME, Esserman LJ, et al. Treatment with autologous antigen-presenting cells activated with the HER-2 –based antigen lapuleucel-T: results of a Phase I study in immunologic and clinical activity in HER-2–overexpressing breast cancer. J Clin Oncol. 2007;25(24):3680–3687. doi:10.1200/JCO.2006.10.5718
   PubMed Web of Science ®Google Scholar
• Larocca C, Schlom J. Viral vector–based therapeutic cancer vaccines. Cancer J. 2011;17(5):359. doi:10.1097/PPO.0b013e3182325e63
   PubMed Web of Science ®Google Scholar
• Disis ML, Coveler AL, Higgins D, et al. A Phase I Trial of the Safety and Immunogenicity of a DNA-Based Vaccine Encoding the HER2/Neu (HER2) Intracellular Domain in Subjects with HER2+ Breast Cancer. American Society of Clinical Oncology; 2014.
   Google Scholar
• Criscitiello C, Corti C, Pravettoni G, et al. Managing side effects of immune checkpoint inhibitors in breast cancer. Critical Rev Oncol. 2021;162:103354. doi:10.1016/j.critrevonc.2021.103354
   Google Scholar
• Bykov VJ, Eriksson SE, Bianchi J, et al. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89–102. doi:10.1038/nrc.2017.109
   PubMed Web of Science ®Google Scholar
• Chung VM, Kos F, Hardwick N, et al. A Phase 1 Study of p53MVA Vaccine in Combination with Pembrolizumab. American Society of Clinical Oncology; 2018.
   Google Scholar
• Jeng L-B, Liao L-Y, Shih F-Y, et al. Dendritic-Cell-vaccine-based immunotherapy for hepatocellular carcinoma: clinical trials and recent preclinical studies. Cancers. 2022;14(18):4380. doi:10.3390/cancers14184380
   PubMed Web of Science ®Google Scholar
• Ke Y, Zhu J, Chu Y, et al. Bifunctional fusion membrane‐based hydrogel enhances antitumor potency of autologous cancer vaccines by activating dendritic cells. Adv Funct Mater. 2022;32(29):2201306. doi:10.1002/adfm.202201306
   Web of Science ®Google Scholar
• Xia D, Li F, Xiang J. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother Radiopharm. 2004;19(3):322–330. doi:10.1089/1084978041424990
   PubMed Web of Science ®Google Scholar
• Avigan D, Rosenblatt J, Kufe D. Dendritic/Tumor Fusion Cells as Cancer Vaccines. in Seminars in Oncology. Elsevier; 2012.
   Google Scholar
• Narayanan K, Jaramillo A, Benshoff ND, et al. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. J Natl Cancer Inst. 2004;96(18):1388–1396. doi:10.1093/jnci/djh261
   PubMedGoogle Scholar
• Liao F, Zhang J, Hu Y, et al. Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells. Cancer Immunol Immunother. 2022;71(8):1959–1973. doi:10.1007/s00262-021-03129-6
   PubMed Web of Science ®Google Scholar
• Chopra A, Kim TS, O‐Sullivan I, et al. Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA‐based cell vaccine. Int j Cancer. 2006;118(11):2888–2898. doi:10.1002/ijc.21724
   PubMed Web of Science ®Google Scholar
• Hsu C, Kavathas P, Herzenberg LA. Cell-surface antigens expressed on L-cells transfected with whole DNA from non-expressing and expressing cells. Nature. 1984;312(5989):68–69. doi:10.1038/312068a0
   PubMed Web of Science ®Google Scholar
• Kavathas P, Herzenberg LA. Stable transformation of mouse L cells for human membrane T-cell differentiation antigens, HLA and beta 2-microglobulin: selection by fluorescence-activated cell sorting. Proc Natl Acad Sci. 1983;80(2):524–528. doi:10.1073/pnas.80.2.524
   PubMed Web of Science ®Google Scholar
• Karim AM, Eun Kwon J, Ali T, et al. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol. 2023;212:115545. doi:10.1016/j.bcp.2023.115545
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu D, Eling DJ, et al. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res. 1998;58(9):1965–1971.
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011;239(1):62–84. doi:10.1111/j.1600-065X.2010.00980.x
   PubMed Web of Science ®Google Scholar
• Liu MA, Wahren B, Hedestam GBK. DNA vaccines: recent developments and future possibilities. Human Gene Therapy. 2006;17(11):1051–1061. doi:10.1089/hum.2006.17.1051
   PubMed Web of Science ®Google Scholar
• Toussaint B, Chauchet X, Wang Y, et al. Live-attenuated bacteria as a cancer vaccine vector. Exp Rev Vaccines. 2013;12(10):1139–1154. doi:10.1586/14760584.2013.836914
   PubMed Web of Science ®Google Scholar
• Tangney M, Gahan CG. Listeria monocytogenes as a vector for anti-cancer therapies. Curr Gene Therapy. 2010;10(1):46–55. doi:10.2174/156652310790945539
   PubMed Web of Science ®Google Scholar
• Josefsberg JO, Buckland B. Vaccine process technology. Biotechnol Bioeng. 2012;109(6):1443–1460. doi:10.1002/bit.24493
   PubMed Web of Science ®Google Scholar
• Marra F, Cloutier K, Oteng B, et al. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics. 2009;27(2):127–147. doi:10.2165/00019053-200927020-00004
   PubMed Web of Science ®Google Scholar
• Campoli M, et al. Mechanisms of tumor evasion. In: Tumor Immunology and Cancer Vaccines; 2005:61–88.
   Google Scholar
• Dougan M, Dranoff G. Immune therapy for cancer. Ann Rev Immunol. 2009;27(1):83–117. doi:10.1146/annurev.immunol.021908.132544
   PubMedGoogle Scholar
• Bonassi S, Znaor A, Ceppi M, et al. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis. 2007;28(3):625–631. doi:10.1093/carcin/bgl177
   PubMed Web of Science ®Google Scholar
• Hirayama M, Nishimura Y. The present status and future prospects of peptide-based cancer vaccines. Int Immunol. 2016;28(7):319–328. doi:10.1093/intimm/dxw027
   PubMed Web of Science ®Google Scholar
• Pan Q, Li Q, Liu S, et al. Concise review: targeting cancer stem cells using immunologic approaches. Stem Cells. 2015;33(7):2085–2092. doi:10.1002/stem.2039
   PubMed Web of Science ®Google Scholar
• Zhou L, Lu L, Wicha MS, et al. Promise of cancer stem cell vaccine. Hum Vaccin Immunother. 2015;11(12):2796–2799. doi:10.1080/21645515.2015.1083661
   PubMed Web of Science ®Google Scholar
• Teitz-Tennenbaum S, Wicha MS, Chang AE, et al. Targeting cancer stem cells via dendritic-cell vaccination. Oncoimmunology. 2012;1(8):1401–1403. doi:10.4161/onci.21026
   PubMed Web of Science ®Google Scholar
• Yu J, Sun H, Cao W, et al. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol. 2022;11(1):3. doi:10.1186/s40164-022-00257-2
   PubMed Web of Science ®Google Scholar
• Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8. doi:10.1038/s41392-020-0110-5
   PubMed Web of Science ®Google Scholar
• Akbar Samadani A, Keymoradzdeh A, Shams S, et al. Mechanisms of cancer stem cell therapy. Clin Chim Acta. 2020;510:581–592. doi:10.1016/j.cca.2020.08.016
   PubMed Web of Science ®Google Scholar
• Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20. doi:10.1186/s12929-018-0426-4
   PubMed Web of Science ®Google Scholar
• Velasco-Velázquez MA, Homsi N, De La Fuente M, et al. Breast cancer stem cells. Int j Biochemistry Cell Biol. 2012;44(4):573–577. doi:10.1016/j.biocel.2011.12.020
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Wong G, Earle C, et al. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010;285(47):36721–36735. doi:10.1074/jbc.M110.162305
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100(7):3983–3988. doi:10.1073/pnas.0530291100
   PubMed Web of Science ®Google Scholar
• Ye F, Qiu Y, Li L, et al. The presence of EpCAM - /CD49f + cells in breast cancer is associated with a poor clinical outcome. J Breast Cancer. 2015;18(3):242–248. doi:10.4048/jbc.2015.18.3.242
   PubMed Web of Science ®Google Scholar
• Lo P-K, Kanojia D, Liu X, et al. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin–TGFβ signaling. Oncogene. 2012;31(21):2614–2626. doi:10.1038/onc.2011.439
   PubMed Web of Science ®Google Scholar
• Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Br Cancer Res. 2008;10(1):1–16. doi:10.1186/bcr1855
   Web of Science ®Google Scholar
• Vassilopoulos A, Wang R-H, Petrovas C, et al. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int J Bio Sci. 2008;4(3):133. doi:10.7150/ijbs.4.133
   Google Scholar
• Marcato P, Dean CA, Pan D, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells. 2011;29(1):32–45. doi:10.1002/stem.563
   PubMed Web of Science ®Google Scholar
• Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13(8b):2236–2252. doi:10.1111/j.1582-4934.2008.00455.x
   PubMed Web of Science ®Google Scholar
• Sun M, Yang C, Zheng J, et al. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense. Acta Biomater. 2015;28:171–182. doi:10.1016/j.actbio.2015.09.029
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yu F, Jiao Y, et al. Reduced miR-128 in breast tumor–initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 2011;17(22):7105–7115. doi:10.1158/1078-0432.CCR-11-0071
   PubMed Web of Science ®Google Scholar
• Bai X, Chen Y, Hou X, et al. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab. Rev. 2016;48(4):541–567. doi:10.1080/03602532.2016.1197239
   PubMed Web of Science ®Google Scholar
• Chen D, Bhat-Nakshatri P, Goswami C, et al. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res. 2013;73(18):5821–5833. doi:10.1158/0008-5472.CAN-13-1080
   PubMed Web of Science ®Google Scholar
• Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnol. 2013;31(6):539–544. doi:10.1038/nbt.2576
   PubMed Web of Science ®Google Scholar
• Hwang-Verslues WW, Kuo W-H, Chang P-H, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One. 2009;4(12):e8377. doi:10.1371/journal.pone.0008377
   PubMed Web of Science ®Google Scholar
• Battula VL, Shi Y, Evans KW, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Investig. 2012;122(6):2066–2078. doi:10.1172/JCI59735
   PubMed Web of Science ®Google Scholar
• Liang Y-J, Wang C-Y, Wang I-A, et al. Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. Oncotarget. 2017;8(29):47454. doi:10.18632/oncotarget.17665
   PubMedGoogle Scholar
• Zeng X, Liu C, Yao J, et al. Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications. Pharmacol Res. 2021;163:105320. doi:10.1016/j.phrs.2020.105320
   PubMed Web of Science ®Google Scholar
• Zhang W, Kong X, Ai B, et al. Research progresses in immunological checkpoint inhibitors for breast cancer immunotherapy. Front Oncol. 2021;11:582664. doi:10.3389/fonc.2021.582664
   PubMed Web of Science ®Google Scholar
• Lu H, Chen I, Shimoda LA, et al. Erratum: chemotherapy-Induced Ca2+ release stimulates breast cancer stem cell enrichment (Chemotherapy-Induced Ca^ 2^+ release stimulates breast cancer stem cell enrichment). Cell Rep. 2021;34(1):108605. doi:10.1016/j.celrep.2020.108605
   PubMed Web of Science ®Google Scholar
• Liu Q, Hodge J, Wang J, et al. Emodin reduces breast cancer lung metastasis by suppressing macrophage-induced breast cancer cell epithelial-mesenchymal transition and cancer stem cell formation. Theranostics. 2020;10(18):8365. doi:10.7150/thno.45395
   PubMed Web of Science ®Google Scholar
• Gilani RA, Phadke S, Bao LW, et al. Retraction: UM-164: A Potent c-Src/p38 Kinase Inhibitor with in vivo Activity Against Triple-Negative Breast Cancer. AACR; 2020.
   Google Scholar